Table 1.
Characteristics of the studies included in this meta-analysis.
| Author, year | Histology | Masking | Line | Treatment arm | HR (95% CI) for PFS | HR (95% CI) for OS |
|---|---|---|---|---|---|---|
| Horn 2018 | SCLC | Double-Blind | 1 | Atezolizumab + CE vs Placebo + CE | 0.77 (0.62–0.96) | 0.70 (0.54–0.91) |
| Cohen 2018 | HNC | Open-Label | >1 | Pembrolizumab vs IC of Standard-of-care Therapy | 0.96 (0.79–1.16) | 0.80 (0.65–0.98) |
| Schmid 2018 | BC | Double-Blind | 1 | Atezolizumab + Nab-Paclitaxel vs Placebo + Nab-Paclitaxel | 0.80 (0.69–0.92) | 0.84 (0.69–1.02) |
| Powles 2018 | UC | Open-Label | >1 | Atezolizumab vs ICC | NA | 0.85 (0.73–0.99) |
| Paz-Ares 2018 | NSCLC | Double-Blind | 1 | Pembrolizumab + ICC vs Placebo + ICC | 0.56 (0.45–0.70) | 0.64 (0.49–0.85) |
| Larkin 2018 | Mm | Open-Label | >1 | Nivolumab vs ICC | 1.03 (0.78–1.44) | 0.95 (0.73–1.24) |
| Herbst 2016 | NSCLC | Open-Label | >1 | Pembrolizumab 2 mg/kg vs Docetaxel | 0.88 (0.74–1.05) | 0.71 (0.58–0.88) |
| Pembrolizumab 10 mg/kg vs Docetaxel | 0.79 (0.66–0.94) | 0.61 (0.49–0.75) | ||||
| Gandhi 2018 | NSCLC | Double-Blind | 1 | Pembrolizumab + IC of PT-DC vs Placebo + IC of PT-DC | 0.52 (0.43–0.64) | 0.49 (0.38–0.64) |
| Fehrenbacher 2018 | NSCLC | Open-Label | >1 | Atezolizumab vs Docetaxel | 0.96 (0.85–1.08) | 0.80 (0.70–0.92) |
| Barlesi 2018 | NSCLC | Open-Label | >1 | Avelumab vs Docetaxel | 1.16 (0.97–1.40) | 0.90 (0.75–1.08) |
| Antonia 2018 | NSCLC | Double-Blind | >1 | Durvalumab vs Placebo | 0.51 (0.41–0.63) | 0.68 (0.47–0.997) |
| Reck 2016 | NSCLC | Open-Label | 1 | Pembrolizumab vs IC of PT-DC | 0.50 (0.37–0.68) | 0.60 (0.41–0.89) |
| Kang 2017 | GC/GEJC | Double-Blind | >1 | Nivolumab vs Placebo | 0.60 (0.49–0.75) | 0.63 (0.51–0.78) |
| Carbone 2017 | NSCLC | Open-Label | 1 | Nivolumab vs IC of PT-DC | 1.19 (0.97–1.46) | 1.08 (0.87–1.34) |
| Bellmunt 2017 | UC | Open-Label | >1 | Pembrolizumab vs ICC | 0.98 (0.81–1.19) | 0.73 (0.59–0.91) |
| Borghaei 2015 | NSCLC | Open-Label | >1 | Nivolumab vs Docetaxel | 0.92 (0.77–1.11) | 0.73 (0.59–0.89) |
| Brahmer 2015 | NSCLC | Open-Label | >1 | Nivolumab vs Docetaxel | 0.62 (0.47–0.81) | 0.59 (0.44–0.79) |
| Motzer 2015 | RCC | Open-Label | >1 | Nivolumab vs Everolimus | 0.88 (0.75–1.03) | 0.73 (0.57–0.93) |
| Fehrenbacher 2016 | NSCLC | Open-Label | >1 | Atezolizumab vs Docetaxel | 0.94 (0.72–1.23) | 0.73 (0.53–0.99) |
| Ferris 2016 | HNC | Open-Label | >1 | Nivolumab vs IC of Standard, Single-agent Therapy | 0.89 (0.70–1.13) | 0.70 (0.51–0.96) |
| Socinski 2018 | NSCLC | Open-Label | 1 | Atezolizumab + Bev + PC vs Bev + PC | 0.61 (0.52–0.72) | NA |
| Ascierto 2018 | Mm | Double-Blind | 1 | Nivolumab vs Dacarbazine | 0.42 (0.33–0.53) | 0.46 (0.36–0.59) |
| Bang 2018 | GC/GEJC | Open-Label | >1 | Atezolizumab vs ICC | 1.73 (1.40–2.20) | 1.10 (0.90–1.40) |
| Mateos 2019 | MM | Open-Label | >1 | Pembrolizumab plus PD vs PD | 1.53 (1.05–2.22) | 1.61 (0.91–2.85) |
| Usmani 2019 | MM | Open-Label | 1 | Pembrolizumab plus LD vs LD | 1.22 (0.67–2.22) | 2.06 (0.93–4.55) |
| Borghaei 2019 | NSCLC | Open-Label | 1 | Pembrolizumab plus Pemetrexed-Carboplatin vs Pemetrexed-Carboplatin | 0.53 (0.33–0.86) | 0.56 (0.32–0.95) |
| Eng 2019 | CRC | Open-Label | >1 | Atezolizumab plus Cobimetinib vs Regorafenib | 1.25 (0.94–1.65) | 1.00 (0.73–1.38) |
| Atezolizumab vs Regorafenib | 1.39 (1.00–1.94) | 1.19 (0.83–1.71) | ||||
| Fradet 2019 | UC | Open-Label | >1 | Pembrolizumab vs ICC | 0.96 (0.79–1.16) | 0.70 (0.57–0.85) |
| Hamid 2019 | Mm | Double-Blind | >1 | Pembrolizumab 2 mg/kg vs ICC | 0.58 (0.46–0.73) | 0.79 (0.58–1.08) |
| Pembrolizumab 10 mg/kg vs ICC | 0.47 (0.37–0.60) | 0.67 (0.49–0.92) | ||||
| Mok 2019 | NSCLC | Open-Label | 1 | Pembrolizumab vs IC of PT-DC | 1.07 (0.94–1.21) | 0.81 (0.71–0.93) |
| Motzer 2019 | RCC | Open-Label | 1 | Avelumab plus Axitinib vs Sunitinib | 0.69 (0.56–0.84) | 0.78 (0.55–1.08) |
| Weber 2015 | Mm | Open-Label | >1 | Nivolumab vs ICC | 0.82 (0.32–2.05) | NA |
| West 2019 | NSCLC | Open-Label | 1 | Atezolizumab plus IC of PT-DC vs IC of PT-DC | 0.65 (0.54–0.77) | 0.80 (0.65–0.99) |
| Brian 2019 | RCC | Open-Label | 1 | Atezolizumab plus Bev vs Sunitinib | 0.83 (0.70–0.97) | 0.93 (0.76–1.14) |
| Rini 2019 | RCC | Open-Label | 1 | Pembrolizumab plus Axitinib vs Sunitinib | 0.69 (0.57–0.84) | 0.53 (0.38–0.74) |
Abbreviations: NSCLC, Non-Small Cell Lung Cancer; SCLC, Small Cell Lung Cancer; Mm, Melanoma; RCC, Renal-Cell Carcinoma; UC, Urothelial Carcinoma; GC/GEJC, Gastric or Gastro-oesophageal Junction Cancer; BC, Breast Cancer; HNC, Head-and-Neck Cancer, MM, Multiple Myeloma. CE, Carboplatin plus Etoposide; IC, Investigator’s Choice; ICC = Investigator’s Choice of Chemotherapy; PT-DC, Platinum-Based Doublet Chemotherapy; PC, Paclitaxel plus Carboplatin; Bev, Bevacizumab; Pomalidomide plus Dexamethasone, PD; Pembrolizumab plus Lenalidomide and Dexamethasone, LD. Lenalidomide and Dexamethasone.